TY - JOUR
T1 - Circulating biomarkers for prediction of objective response to chemotherapy in pancreatic cancer patients
AU - van der Sijde, Fleur
AU - Vietsch, Eveline E.
AU - Mustafa, Dana A. M.
AU - Besselink, Marc G.
AU - Koerkamp, Bas Groot
AU - van Eijck, Casper H. J.
PY - 2019
Y1 - 2019
N2 - Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive care, many individual patients may not benefit from chemotherapy. Biomarkers are needed to predict who will benefit from chemotherapy and to monitor a patient’s response to chemotherapy. This review summarizes current research and future perspectives on circulating biomarkers for systemic chemotherapy response.
AB - Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive care, many individual patients may not benefit from chemotherapy. Biomarkers are needed to predict who will benefit from chemotherapy and to monitor a patient’s response to chemotherapy. This review summarizes current research and future perspectives on circulating biomarkers for systemic chemotherapy response.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85061991379&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30650521
U2 - https://doi.org/10.3390/cancers11010093
DO - https://doi.org/10.3390/cancers11010093
M3 - Review article
C2 - 30650521
SN - 2072-6694
VL - 11
JO - Cancers
JF - Cancers
IS - 1
M1 - 93
ER -